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The cellular protein hnRNP A2/
B1 enhances HIV-1 transcription 
by unfolding LTR promoter 
G-quadruplexes
Matteo Scalabrin*, Ilaria Frasson*, Emanuela Ruggiero*, Rosalba Perrone, Elena Tosoni, 
Sara Lago, Martina Tassinari, Giorgio Palù & Sara N. Richter
G-quadruplexes are four-stranded conformations of nucleic acids that act as cellular epigenetic 
regulators. A dynamic G-quadruplex forming region in the HIV-1 LTR promoter represses HIV-1 
transcription when in the folded conformation. This activity is enhanced by nucleolin, which induces 
and stabilizes the HIV-1 LTR G-quadruplexes. In this work by a combined pull-down/mass spectrometry 
approach, we consistently found hnRNP A2/B1 as an additional LTR-G-quadruplex interacting protein. 
Surface plasmon resonance confirmed G-quadruplex specificity over linear sequences and fluorescence 
resonance energy transfer analysis indicated that hnRNP A2/B1 is able to efficiently unfold the LTR 
G-quadruplexes. Evaluation of the thermal stability of the LTR G-quadruplexes in different-length 
oligonucleotides showed that the protein is fit to be most active in the LTR full-length environment. 
When hnRNP A2/B1 was silenced in cells, LTR activity decreased, indicating that the protein acts as a 
HIV-1 transcription activator. Our data highlight a tightly regulated control of transcription based on 
G-quadruplex folding/unfolding, which depends on interacting cellular proteins. These findings provide 
a deeper understanding of the viral transcription mechanism and may pave the way to the development 
of drugs effective against the integrated HIV-1, present both in actively and latently infected cells.
G-quadruplexes (G4s) are unique four-stranded nucleic acid structures that may form in guanine-rich sequences. 
Based on the strand orientation, they can adopt three main topologies: parallel, antiparallel, and hybrid-type 
structures. G4s have been shown to be involved in key regulatory and pathological roles in eukaryotes, including 
transcriptional regulation of gene promoters and enhancers, translation, chromatin epigenetic regulation, DNA 
recombination1–3. Formation of G4 in vivo has been consolidated by the development of G4 specific antibodies4,5.
Recently, the presence of G4s in viruses and their involvement in key steps of viral infection has been pro-
vided6. G4s have been reported in the SARS coronavirus7, the human papilloma, hepatitis C, Zika and Ebola virus 
genomes8–11. Among herpesviruses, RNA G4s have been implicated in the regulation of DNA replication and 
translation of the Epstein–Barr virus12,13. We have shown that the herpes simplex virus 1 possesses several repeats 
of sequences forming stable G4s, which were visualized in infected cells by a G4-specific antibody14; stabilization 
of these tetraplex structures by a G4 ligand inhibited viral DNA replication15.
The largest body of evidence of G4-mediated regulation of viruses has been provided for the human immu-
nodeficiency virus-1 (HIV-1), the etiologic agent of the acquired immune deficiency syndrome (AIDS). We 
and other groups have identified functionally significant G4s in the Nef coding region16 and in the unique long 
terminal repeat (LTR) promoter17–19 of HIV-1. When the HIV-1 G4s were stabilized by G4 ligands, antiviral 
effects, mainly dependent on inhibition of LTR-mediated transcription, were observed18,20,21. Furthermore, the 
cellular protein nucleolin has been shown to stabilize the HIV-1 LTR G4s and induce potent inhibition of viral 
transcription22.
In general, several proteins that modulate G4s and/or serve as a bridge to recruit additional protein regula-
tors have been reported23. Besides the shelterin complex proteins that are involved in telomere homeostasis24, 
G4 interacting proteins either stabilize (e.g. nucleolin, MAZ and nucleophosmin) or unfold (the helicase and 
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heterogeneous nuclear ribonucleoprotein (hnRNP) families)25,26 the G4 conformation to allow for a tightly con-
trolled modulation of the epigenetic G4 switch.
By means of mass spectrometry, surface plasmon resonance (SPR), fluorescence energy transfer (FRET), Taq 
polymerase stop and reporter assays, we here identified and characterized G4-selectivity and function of the 
hnRNP A2/B1, the first protein shown to unfold G4s in the HIV-1 LTR promoter.
Results
The human nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) selectively binds the HIV-1 LTR 
G-quadruplexes. We have shown that the HIV-1 LTR promoter can fold into three mutually exclusive G4s 
and that nucleolin, the most abundant nucleolar protein, can bind, induce and stabilize the LTR G4s22. We rea-
soned that other proteins may exist that regulate the G4/ds equilibrium at the LTR: we thus looked for additional 
proteins by pull-down assay of 293T nuclear cell extracts against the whole region in the HIV-1 LTR that can fold 
into G4, i.e. LTR-II + III + IV. This region can alternatively fold into three G4s, i.e. LTR-II, LTR-III and LTR-IV. As 
control, a two-point mutation LTR-II + III + IV oligonucleotide, which has been previously shown to be unable 
to fold into G4, i.e. LTR-II + III + IV M4 + 5, was used (Fig. 1a and Supplementary Table S1)18. After washing at 
increasing ionic strength to destabilize weak protein-G4 interactions, the final eluted sample was run on SDS-
PAGE and subjected to MS analysis. A series of heterogeneous nuclear ribonucleoproteins (hnRNPs) were found 
to be present only in the G4-folded oligonucleotide (Table 1); among them, only hnRNP A2/B1 was obtained 
in all three independent tests, even if it did not obtain the highest score within each experiments (Fig. 1b). The 
identity and selectivity of hnRNP A2/B1 was confirmed by pull-down assay followed by western blot analysis 
with an anti-hnRNP A2/B1 antibody. The G4-folded LTR-II + III + IV was used along with the G-rich non-G4 
forming LTR-II + III + IV M4 + 5 and a random oligonucleotide of the same length (Supplementary Table S1). 
The hnRNP A2/B1 protein was confirmed to bind mainly to the G4-folded sequence, even if in these settings it 
displayed mild recognition also of the G-rich non-G4-folding oligonucleotide (Fig. 1c). To confirm selectivity 
toward the G4 LTR oligonucleotide, surface plasmon resonance (SPR) analysis was performed. The recombi-
nant purified hnRNP A2, which lacks 12 amino acids in the amino-terminal region and is the main isoform, 
accounting for ~90% of the protein in most tissues27, was immobilized on a SPR chip and binding affinity of the 
unlabelled oligonucleotides was measured. LTR-II + III + IV displayed the highest KD (19.5 ± 1.5 nM), while the 
Figure 1. (a) LTR-II + III + IV sequence of the G-rich LTR region comprising tracts that fold into three 
mutually exclusive LTR G4s, i.e. LTR-II, LTR-III and LTR-IV. These three-stacked tetrads G4s are indicated in 
brackets. G bases in G-tracts or involved in G-quadruplexes are shown in bold. (b) MS/MS spectrum of the 
precursor ion observed at m/z 1095.46 in the sample mixture from digestion of LTR-II + III + IV G4 sample 
(see Table 1). Only characteristic y ions are indicated53. The data match the sequence of peptide N326-R350 of 
hnRNP A2/B1, which is reported on top with the observed fragments. c) Pull-down assay of nuclear extract 
proteins with wt, mutant G4 LTR-II + III + IV (M) and random (R) sequences, immobilized on agarose beads. 
Shown is the western blot analysis with an anti-hnRNP A2/B1 antibody. Proteins complexed to the beads-
bound LTRs were washed with augmented stringency by increasing the ionic strength of the wash buffer (0.2 
and 1 M). The final elution was obtained in denaturing buffer at 95 °C.
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mutant LTR-II + III + IV M4 + 5 was bound with a lower affinity (KD 35.5 ± 3.0 nM). Chi2 and U-values were 
< 10 and < 15, respectively, indicating optimal data fitting28,29. In contrast, binding to a random oligonucleotide of 
the same length as LTR-II + III + IV was so low that in these conditions it was not possible to obtain a meaningful 
KD value (Fig. 2).
hnRNP A2 unfolds the LTR G4s. We next set out to investigate the effect of hnRNP A2 binding to the 
LTR G4s. A Taq polymerase stop assay was performed on the LTR-II + III + IV template. In the presence of 
100 mM K+, stop sites corresponding to formation of LTR-III and LTR-II were visible (compare lanes 1 and 2, 
Fig. 3a). No stop corresponding to LTR-IV was detected, as expected, since LTR-IV has been previously reported 
to form upon induction by G4 ligands18. Upon addition of hnRNP A2, both LTR-III and LTR-II stop sites showed 
an insignificant decrease (compare lanes 3 and 2, Fig. 3a and b). Similarly, no effect was induced by addition of 
K+ and hnRNP A2 in the control LTR-II + III + IV M4 + 5 template lacking the possibility to form G4 (lanes 5–7, 
Fig. 3a).
As suggested by Xodo30, the apparent lack of effect in the presence of an unfolding protein could be due to 
the protein binding to the template sequence which would stimulate polymerase stop and mask G4 release at the 
same binding site. We thus switched to a dual-labelled system where oligonucleotide folding could be monitored 
by changes in fluorescence. Fluorescence resonance energy transfer (FRET) is a spectroscopic technique that 
provides information about structure and dynamics of nucleic acids folding. It involves a donor fluorophore in 
an excited state, the excitation energy of which can be transferred to a proximal acceptor chromophore. Given 
that the major determinant of FRET efficiency is the distance between the acceptor and the donor, fluorescence 
intensities depict nucleic acids folding states. Consequently, when annealed to its complementary sequence to 
form a double-stranded structure, the tested oligonucleotide would yield the maximum fluorescence intensity, 
while the G4 folded conformation would be the least fluorescent. In these conditions the measured fluorescence 
intensity allows to calculate the energy transfer (E) and the end-to-end distance (R) between the two fluoro-
phores, and therefore the unfolding degree. The G4 folded LTR-II + III + IV sequence was characterized by 
R of ~38Ǻ, with E ~0.84. When the G4 structure was converted into the duplex conformation by addition of 
the complementary C-rich strand, the fluorophores were separated by ~150 Ǻ, and FRET was approximately 
0. Treatment of LTR-II + III + IV G4 with hnRNP A2 increased fluorescence by 3-folds with respect to the free 
G4, and E decreased to 0.51 (Fig. 4a and b, Supplementary Table S2). Considering that the complete unfold-
ing of the G4 structure required Δ E = 0.72, the Δ E = 0.30 induced by hnRNP A2 reflected a 42% unfolding 
(Fig. 4c). The negative control protein BSA showed negligible unfolding activity in these conditions (Fig. 4c and 
Supplementary Table S2). To test the statistical significance of the effect observed in the presence of the pro-
tein, we applied a model comparison approach, which allows to test the statistical role of an independent vari-
able (in our case the hnRNP A2 protein) through the comparison of two models differing only in that variable. 
The test yielded F (2, 189) = 36.27 and P < 0.0531, indicating that the difference observed in the presence and 
absence of the protein was statistically significant. Analysis of the activity of hnRNP A2 was extended to shorter 
LTR sequences, i.e. LTR-III + IV, LTR-III and LTR-IV G4s, folded in 100 mM K+. The unfolding of LTR-III + IV 
and LTR-IV was similar but lower than that on the full-length sequence (31%); unfolding of LTR-III was very 
low (8.5%) (Fig. 4c, Supplementary Table S1 and Supplementary Fig. S2–S4) When the G4-forming sequences 
were folded in lower K+ concentrations, i.e. 50 and 25 mM, a distinct enhancement of unfolding was observed: 
Exp#
Experimental 
monoisotopic 
mass
Expected 
monoisotopic 
mass Protein match
Peptide 
match Score*
1 1921.102 1921.079 Putative zinc finger protein 812 V145-R162 18
1, 
2, 3
2188.904
2219.053
2188.898
2219.063
Heterogeneous nuclear
ribonucleoprotein A2/B1
N326-R350
D130-R147
27
18
1 2429.146 2429.157 Heterogeneous nuclear ribonucleoprotein D0 I198-K218 31
2 1681.900 1681.907 Heterogeneous nuclear ribonucleoprotein C1/C2 M74-K89 39
2 863.487 863.487 Mediator of RNA polymerase II transcription subunit 11 V97-K103 22
2 1036.698 1036.676 Histone H1.2 A192-K201 20
2 1036.698 1036.687 Transcription factor AP-4 R294-R302 18
3 952.346 952.349 Cysteine/serine-rich nuclear protein 2 D249-R257 16
3 3450.685 3450.699 Non-POU domain-containing octamer-binding protein G399-R434 28
Table 1.  MS analysis of protein content of three independent experiments and collected from SDS 
gels. *The score (assigned on probabilistic bases by mascot software, “http://www.matrixscience.com/help/
interpretation_help.html#THRESHOLDS”)51 is the probability that the observed match is not a random event. 
The score is reported as − 10x log10(P) where P is the absolute probability. The mass of the putative peptides and 
of the 50 most intense fragment ions were used for the data base search. Significant Mascot hits were accepted as 
positive matches and their ion score reported. The highest score obtained in the three experiments is reported.
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unfolding up to 83% was obtained in the LTR-II + III + IV oligonucleotide (Fig. 4c, Supplementary Table S1 and 
Supplementary Fig. S1).
Because G4s are less stable at lower K+ concentrations, we proposed that the diverse unfolding efficiency 
towards the different-length LTR G4s depended on the stability of the LTR G4s. To test this hypothesis, melting 
temperatures (Tm) of the dual-labelled oligonucleotides were thus measured by FRET-monitored thermal unfold-
ing (Table 2). The most stable sequence was LTR-III (Tm 62.1 ± 0.1 °C), followed by LTR-IV and LTR-III + IV 
(Tm 59.1 ± 0.1 °C and 55.2 ± 0.1 °C, respectively); LTR-II + III + IV was the least stable sequence (Tm 49.1 ± 0.1), 
confirming that the observed unfolding scale depended on the oligonucleotide stability in the FRET system. To 
note that in the unlabelled oligonucleotides measured by circular dichroism (CD), LTR-IV was the least stable 
sequence (Table 2), bias which likely derives by the absence of fluorophores at the oligonucleotides’ 5′ - and 3′ -end, 
which affect Tm values, as previously noted32.
In addition, the longest sequences, i.e. LTR-II + III + IV and LTR-III + IV, where multiple G4s may form, dis-
play Tm values that represent the average stability, which depends on the effective formation of the possible G4s. 
We thus performed a Taq polymerase stop assay to assess the G4 mutual formation and stability at increasing K+ 
concentration in the full-length LTR. LTR-III was used as a control sequence where only one G4 could form. We 
observed that in the full-length LTR-II + III + IV sequence, both LTR-II and LTR-III G4s formed upon addition 
of K+ (lanes 2–3, Fig. 5a); of these, LTR-III G4 induced a slightly more intense stop than LTR-II, suggesting a 
preferred formation of LTR-III in the full-length sequence (Fig. 5b). LTR-III was also the only G4 forming in the 
LTR-III + IV template (lanes 5–7, Fig. 5a). Interestingly, the LTR-III that formed in the full-length sequence was 
less intense than LTR-III forming in the shortest oligonucleotides (compare lanes 2–3, with 6–7 and 9–10, Fig. 5a 
and b). These data indicate that i) LTR-III is the most prominent G4 among the mutually exclusive LTR G4s and ii) 
Figure 2. Binding affinity of hnRNP A2 for the LTR-II + III + IV G4 and mutant sequences measured 
by surface plasmon resonance (SPR) analysis. The human recombinant hnRNP A2 was immobilized on 
the SPR chip by amine coupling chemistry and the unlabelled oligonucleotides were bound at a flow rate of 
25 μ l/min, with contact time and dissociation time of 120 s in HEPES-KCl buffer. Sensograms were obtained 
in the oligonucleotide concentration range of 31.25 nM–2 μ M. SPR sensograms of (a) LTR-II + III + IV 
with ka 4.7 × 104 ± 5.2 × 102 Ms−1 and kd 9.2 × 10−4 ± 7.5 × 10−5 s−1, (b) LTR-II + III + IV M4-5 with ka 
2.8 × 104 ± 3.4 × 102 Ms−1 and kd 10.0 × 10−4 ± 8.4 × 10−5 s−1 and (c) LTR-II + III + IV Random, the ka and kd 
values of which are not reliably measurable. Sensograms are shown as grey lines and their respective fits as black 
lines.
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Figure 3. Taq polymerase stop assay in the presence of hnRNP A2. (a) Taq polymerization was performed 
in the presence/absence of K+ and hnRNP A2, as indicated, on the wt and the mutant LTR-II + III + IV M4 + 5 
sequences. Amplification of the wt template was performed at 37 °C for 30 min. Stop regions corresponding to 
LTR-III are indicated by the * symbol, to LTR-II by § and to LTR-IV by#. M is a marker lane obtained with the 
Maxam & Gilbert sequencing protocol. P indicates the band of the labelled primer. (b) Quantification of lanes 
1–3 in panel (a). Quantification of stop bands corresponding to formation of LTR-II and LTR-III G4s and of the 
full-length amplification product (FL) is shown.
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when LTR-III forms in the full-length LTR promoter, its stability maintains a level that is fully susceptible to 
hnRNP A2 processing.
Depletion of hnRNP A2/B1 decreases viral transcription. We have shown that LTR G4 folding inhib-
its viral transcription, whereas when point mutations that disrupt G4s are introduced in the LTR promoter, an 
increase in promoter activity is evidenced18. Silencing of the LTR G4 folding/stabilizing protein nucleolin signif-
icantly increased promoter activity, indicating the inhibitory effect of nucleolin on LTR-driven transcription22. 
To assess the effect of hnRNP A2/B1 binding/unfolding of the full-length LTR G4s, a set of anti-hnRNP A2/B1 
siRNAs was used, which effectively silenced hnRNP A2/B1 expression in 293T cells (Fig. 6a). In these conditions, 
LTR-driven transcription decreased by 45% at the highest siRNA concentration in the wt LTR sequence (Fig. 6b). 
In contrast, the LTR sequence with two point mutations that disrupt G4 folding was only marginally affected by 
hnRNP A2/B1 depletion (Fig. 6b), indicating that the effect was G4-specific. In these conditions, hnRNP A2/
B1-silenced 293T cells showed no reduction in cell viability at 48 h with respect to the controls, thus confirming 
Figure 4. FRET analysis of hnRNP A2 unfolding. (a) FRET-melting curves of LTR F-II + III + IV-T, in the 
absence or presence of hnRNP A2 1:10 or of BSA as control. (b) Corresponding first derivative curves, dF/dT 
versus T. Proteins were incubated with the LTR G4s for 30 min at 37 °C prior to analysis. (c) Unfolding % of 
all tested sequences at 100, 50, 25 mM K+, incubated in the presence of hnRNP A2 or BSA at 37 °C for 30 min. 
Unfolding values are referred to unfolding in the absence of proteins (100%).
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the consistency of the inhibitory effects on LTR promoter activity. Silencing of hnRNP A2/B1 was also performed 
in the TZM-bl reporter cell line, which contains stably integrated copies of the luciferase gene under control of 
the LTR wt promoter and thus closely resembles the integrated provirus. The LTR-driven reporter transcription 
decreased up to 33% in hnRNP A2/B1-silenced cells (Supplementary Fig. S5). These data further confirm the 
unfolding activity of hnRNP A2/B1 on the LTR G4s.
Discussion
We have shown that hnRNP A2/B1 selectively binds the HIV-1 LTR G4s and unfolds them. While hnRNPs are 
RNA/protein complexes that bind newly synthesized RNA (pre-mRNA) in the cell nucleus during gene transcrip-
tion and post-transcriptional modifications33, two of the most abundant of them, hnRNP A1 and hnRNP A2/B1, 
have been reported to bind also DNA in the quadruplex conformation. Initially hnRNP A1 was found to unfold 
the telomeric G4s and promote telomerase activity34–36, to unfold the G4 in the promoter of the KRAS oncogene 
and regulate transcription30 and to destabilize the tetraplex forms of the fragile X expanded sequence d(CGG)n37. 
HnRNP A2 has been shown to unfold the fragile X repeats38 and the shorter hnRNP A2 splice variant to promote 
telomere extension in mammalian cells39.
Our finding that hnRNP A2 binds and unfolds the G4s in the promoter of HIV-1 not only confirms the DNA 
G4 unfolding activity of this protein, but also indicates for the first time that this type of activity is exploited by 
a virus.
In HIV-1, hnRNP A2/B1 has been reported to play with Rev an important accessory role in promoting nuclear 
viral RNA retention and nucleocytoplasmic viral RNA transport40. In this context, the lower virus production 
observed upon siRNA-mediated depletion of hnRNP A2/B1 in infected cells was ascribed to accumulation of 
viral genomic RNA in cytoplasmic compartments or in the nucleus41. Our results showing decreased transcrip-
tional activity upon depletion of hnRNP A2/B1 indicate a possible additional mechanism of inhibition of virus 
production mediated by increased G4 folding in the HIV-1 LTR promoter in the absence of hnRNP A2/B1. 
Surprisingly, overexpression of this protein and other hnRNP members induced similar effects, i.e. inhibition of 
transcription and reduction of virus production42. We suggest that upon stimuli that boost viral transcription (i.e. 
integral release of LTR G4s upon hnRNP A2/B1 massive overexpression) the virus (or the cell) activates coun-
teracting mechanisms to avoid excessive exploitation of the cell by the virus that would lead to fast cell death, in 
the end impairing virus production. Therefore, the reported transcription inhibition might be mediated by other 
factors triggered by hnRNP A2/B1 overexpression.
The activity of hnRNP A2/B1 is fit to unfold the G4s that actually form in the HIV-1 LTR region. In fact, 
G4s folded in short oligonucleotides, such as LTR-III and LTR-IV, which displayed higher thermal stabil-
ity, were only partially unfolded by the protein. In contrast, the same G4 structures folding in a longer context 
(LTR-II + III + IV) were less stable and were effectively processed by hnRNP A2/B1. Obviously, the longer oligo-
nucleotide better mimes the actual G4 condition in the full-length LTR, as also proved by transcription inhibition 
obtained by hnRNP A2/B1 depletion in cells that contained the entire HIV-1 LTR.
The LTR G4 system displays regulating features similar to those described for the c-myc43,44, HRAS26 and 
KRAS oncogene-promoters30,45–47. As in these eukaryotic G4-modulated promoters, the HIV-1 LTR promoter is 
processed by G4 stabilizing (nucleolin)22 and destabilizing proteins (hnRNP A2/B1). Because the LTR promoter 
has been suggested to be the region where viral latency is regulated48,49, the G4 switch may play a role not only in 
activation of effective viral transcription, but also in its shift to latency. Currently, only the actively transcribed 
virus is targeted by antiviral drugs, while eradication of the HIV-1 infection has been made impossible by the 
existence of reservoirs of the latent virus50. Therefore, our findings not only advance our understanding on the 
mechanism of viral transcription but may also constitute a progress from a therapeutic point of view.
LTR K+ (mM)
Tm (°C)
FRET CD
II + III + IV
100 49.1 ± 0.1 61.1 ± 0.2
50 45.1 ± 0.1 nd
25 43.2 ± 0.1 nd
III + IV
100 55.2 ± 0.1 64.6 ± 0.1
50 49.1 ± 0.1 nd
25 46.2 ± 0.1 nd
III
100 62.1 ± 0.1 68.7 ± 0.5
50 56.0 ± 0.1 nd
25 52.1 ± 0.1 nd
IV
100 59.1 ± 0.1 50.6 ± 0.8
50 57.1 ± 0.1 nd
25 51.1 ± 0.1 nd
Table 2.  Melting temperatures (Tm) of LTR G4s measured on dual-labelled oligonucleotides by FRET and 
on unlabelled oligonucleotides by CD. Tm values are reported with standard deviation. Nd stands for “not-
determined”.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:45244 | DOI: 10.1038/srep45244
Figure 5. Taq polymerase stop assay at increasing K+ concentrations. (a) Oligonucleotides were folded in the 
absence or presence of K+ (50–100 mM). Oligonucleotides were used as templates in a Taq polymerase reaction 
at 37 °C. Stop regions corresponding to LTR-III are indicated by the *symbol, to LTR-II by § and to LTR-IV by#. 
P indicates the band of the labelled primer. M is a marker lane obtained with the Maxam & Gilbert sequencing 
protocol. (b) Quantification of lanes 1–10 of panel (a). Quantification of stop bands corresponding to formation 
of LTR-II and LTR-III G4s and of the full-length amplification product (FL) is shown.
www.nature.com/scientificreports/
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Methods
Oligonucleotides and cells. All desalted oligonucleotides were purchased from Sigma-Aldrich, Milan, 
Italy (Supplementary Table S1). TZM-bl (obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH, from Dr. J.C. Kappes, Dr. X. Wu, and Tranzyme Inc.) is a HeLa cell line stably expressing large 
amounts of CD4 and CCR5 and containing integrated copies of the luciferase and β -galactosidase genes under 
control of the HIV-1 promoter. Human embryonic kidney (HEK) 293T (ATCC # CRL-3216) and TZM-bl cells 
were grown in DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat-in-
activated fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Cells were grown in a 
humidified incubator maintained at 37 °C with 5% CO2.
Protein nuclear extraction and pull-down assay. Protein nuclear extracts of HEK 293T cells were 
obtained by using NXTRACT kit (Sigma-Aldrich, Milan, Italy). HEK 293T protein nuclear extracts (150 μ g) 
were incubated with biotinylated LTR-II + III + IV G4, mutated M4 + 5 and random R oligonucleotides folded 
(600 nM) in 250 μ l of reaction containing Tris-HCl 20 mM, pH 8, KCl 30 mM, MgCl2 1.5 mM, protease inhibitor 
cocktail (Sigma-Aldrich, Milan, Italy) 1%, NaF 5 mM, Na3VO4 (Sigma-Aldrich, Milan, Italy) 1 mM, poly [dI-dC] 
(Sigma-Aldrich, Milan, Italy) 1.25 ng/μ l for 2 h at 37 °C. The binding reaction was followed by incubation (2 h at 
37 °C) with 30 μ l of streptavidin-agarose beads (Sigma-Aldrich, Milan, Italy). After PBS and NaCl washes (0.2 and 
1 M), beads were collected by brief centrifugation, resuspended in 50 μ l of Laemmli buffer, and finally incubated 
at 95 °C for 5 min. Supernatants were separated in 12% SDS-PAGE and, after coomassie staining, the gel lanes 
of LTR G4 and LTR M4 + 5 were directly in-gel digested and analysed for protein identification by mass spec-
trometry (MS) (see MS protein identification in ref. 22). Briefly, gel lanes cut in ~0.5 cm pieces were first washed 
with 50% CH3OH and 2.5% acetic acid, dehydrated with CH3CN, then reduced with 30 μ l of DTT (10 mM in 
100 mM NH4HCO3) for 30 min at room temperature; the excess of DTT was next neutralized by alkylation with 
30 μ l of iodoacetamide (50 mM in 100 mM NH4HCO3) for 30 min at room temperature. Bands were washed with 
100 mM NH4HCO3, dehydrated with CH3CN twice, and then digested overnight with 1 μ g of MS-grade trypsin 
(ThermoFisher Scientific, Waltham, MA, USA) in 50 μ l of 50 mM NH4HCO3. Peptides were extracted twice with 
5% formic acid and twice with 50% CH3CN/5% formic acid. The peptide mixture was further desalted in a silica 
nanocolumn (Polymicro Technologies, Phoenix, AZ, USA) packed in house with pinnacle C18 pack material 
(Thermo Fisher Scientific, Waltham, MA, USA). The desalted mixture was finally analyzed by direct infusion 
electrospray ionization (ESI) on a Thermo Fisher Scientific (Waltham, MA, USA) LTQ-Orbitrap Velos mass spec-
trometer utilizing quartz emitters produced in house. A stainless steel wire was inserted through the back-end 
of the emitter to supply an ionizing voltage that ranged between 0.8 and 1.2 kV. Putative peptides present in wt 
LTR-II + III + IV (but not in M4 + 5) samples were submitted to tandem mass spectrometric (MS/MS) analysis. 
The masses of the 50 most intense fragment ions were employed to perform a Mascot Database Search51 to iden-
tify their parent protein. Significant Mascot hits were accepted as positive matches and their ion score reported 
Figure 6. Effect of hnRNP A2/B1 on the HIV-1 LTR promoter in cells. (a) hnRNP A2/B1 depletion in 293T 
cells by siRNAs analysed by western blot with anti hnRNP A2/B1 antibody. Scra indicates scrambled siRNAs. 
Detection of α -tubulin (α t) was used as control. The symbol“/”indicates untreated cells. (b) Analysis of the 
luciferase activity of the wt and M4 + 5 LTR promoters in 293T cells treated with hnRNP A2/B1 siRNAs, 
normalized to protein content.
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(see MS protein identification in ref. 22 for more details). Supernatants were further analysed by Western blot 
with an anti-hnRNP A2/B1 antibody (mouse monoclonal DP3B3; Santa Cruz Biotechnology, Dallas, TX, USA).
Surface plasmon resonance (SPR) analysis. SPR was performed on the Biacore T100 platform (GE 
Healthcare, Life Science, Milan, Italy). About 1000 RU of human recombinant hnRNP A2 (Origene Technologies, 
Rockville, USA) were immobilized on Serie S sensor chip CM5 by amine coupling chemistry. Immobilization 
was performed in HEPES-NaCl running buffer (HEPES pH 7.4 10 mM, NaCl 150 mM, EDTA 3 mM). Flow cell 1 
was blank immobilized to permit reference subtraction. Binding analysis of LTR-II + III + IV, LTR-II + III + IV 
M4 + 5 and LTR-II + III + IV Random sequences was performed at a flow rate of 25 μ l/min, with contact time 
and dissociation time of 120 s in HEPES-KCl buffer (HEPES pH 7.4 10 mM, KCl 150 mM, EDTA 3 mM). 
Oligonucleotides folding into G4 structures was performed in HEPES-KCl buffer after heat denaturation at 95 °C 
for 5 min and gradual cooling at room temperature. Sensograms were obtained in the concentration range of 
31.25 nM–2 μ M. After each oligonucleotide injection the chip surface was regenerated with NaCl 2.5 M solution. 
All sensograms were corrected by double reference subtraction of blank flow cell response and buffer injection 
response. Data were fitted to a global 1:1 binding model using BIAevaluation software (GE Healthcare).
FRET-melting assay. Oligonucleotides were diluted to 0.1 μ M in lithium cacodylate buffer (10 mM, pH 7.4) 
and KCl (indicated in figure legends) heat denatured for 5 min at 95 °C, and folded in G-quadruplex structure at 
room temperature for 16 h. Samples were incubated alone, with hnRNP A2 or bovine serum albumin (BSA, neg-
ative control) and subsequently fluorescence intensity was monitored from 30 °C to 95 °C (1 °C/min) in a 
LightCycler II (Roche, Milan, Italy) by observing 6-carboxyfluorescein (6FAM) emission. FRET efficiency (E) was 
calculated as the total fluorescence intensity of the donor in the absence (ID) and presence of the acceptor (IDA), 
by using E = 1 − (IDA/ID). ID and IDA values were obtained on a LS 55 Fluorescence spectrometer (Perkin Elmer, 
Waltham, MA, USA) setting the excitation wavelength at 480 nm and recording the emission from 500 to 650 nm. 
The dual-labelled oligonucleotide was converted into the corresponding duplex, in which the fluorophores are at 
a distance (R) for which FRET is ~0. R was calculated from FRET efficiency values as = −ER R (1/ ) 10
6 , where 
R0 (Förster distance) is the distance at which energy transfer is 50% of the maximum value. Between FAM and 
TAMRA fluorophores, R0 is assumed to be 50Ǻ26. F-test (F) and the probability (P) values were calculated using 
R statistical environment (v. 3.3.2)31. A conventional alpha = 0.05 was considered to evaluate the test 
significance.
Taq Polymerase Stop Assay. Taq polymerase stop assay was carried out as previously described18,22. 
Briefly, the 5′ -end labelled primer was annealed to its template (Table S1) in lithium cacodylate buffer in the 
presence or absence of KCl (50–100 mM) and by heating at 95 °C for 5 min and gradually cooling to room tem-
perature. Where specified, samples were incubated with 29 ng of human recombinant hnRNP A2 (Origene 
Technologies, Rockville, USA) at 37 °C for 15 min. Primer extension was conducted with 2 U of AmpliTaq Gold 
DNA polymerase (Applied Biosystem, Carlsbad, California, USA) at 37 °C for 30 min. Reactions were stopped by 
ethanol precipitation, primer extension products were separated on a 15% denaturing gel, and finally visualized 
by phosphorimaging (Typhoon FLA 9000).
Circular Dichroism Spectroscopy. DNA oligonucleotides were diluted to a final concentration (4 μ M) in 
lithium cacodylate buffer (10 mM, pH 7.4) and KCl 100 mM. Samples were annealed by heating at 95 °C for 5 min 
and gradually cooled to room temperature overnight. CD spectra were recorded on a Chirascan-Plus (Applied 
Photophysisics, Leatherhead, UK) equipped with a Peltier temperature controller using a quartz cell of 5 mm opti-
cal path length, over a wavelength range of 230–320 nm. For the determination of Tm, spectra were recorded over 
a temperature range of 20–90 °C, with temperature increase of 5 °C. The reported spectra are baseline-corrected 
for signal contributions due to the buffer. Observed ellipticities were converted to mean residue ellipticity 
(θ ) = deg × cm2 × dmol−1 (mol ellip). Tm values were calculated according to the van’t Hoff equation, applied for 
a two-state transition from a folded to unfolded state, assuming that the heat capacity of the folded and unfolded 
states are equal52.
Immunoblot analysis. Immunoblot analysis was performed on cell protein extracts obtained in RIPA Buffer 
(20 mM Tris-HCl pH 7.5; 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 1 mM Na3VO4, 1x 
protease inhibitors). Protein concentrations were quantified using the Pierce® BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL, USA). Each sample was electrophoresed on 10% SDS-PAGE and transferred to a nitrocel-
lulose blotting membrane (Amersham TM Protan TM, GE Healtcare Life science, Milan, Italy) by using trans-blot 
SD semi-dry transfer cell (Bio-Rad Laboratories, Milan, Italy). The membranes were blocked with 2.5% skim milk 
in PBST (0.05% Tween 20 in PBS). Membranes were incubated with the respective primary antibody directed 
against hnRNP A2/B1 (mouse monoclonal; Santa Cruz Biotechnology, Dallas, TX, USA), alpha-tubulin (mouse 
monoclonal; Sigma-Aldrich, Milan, Italy). After three washes in PBST, membranes were incubated with ECL 
Plex Goat-α -Mouse IgG-Cy5 (GE Healthcare Life sciences, Milan, Italy). Images were captured on the Typhoon 
FLA 9000.
siRNA and luciferase reporter assay. Gene-specific pooled siRNA trilencer targeting human hnRNP A2/
B1 and a scrambled negative control duplex were purchased from Origene (human hnRNP A2/B1 Trilencer-27 
Human siRNA, OriGene Technologies, Rockville, MD, USA). 293T cells or TZM-bl reporter cells were trans-
fected with increasing concentrations of siRNA (1, 2, 4 and 8 nM for 293T and 1, 5, 10 nM for TZM-bl cells) 
and scrambled siRNA by using Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher Scientific, Waltham, MA, 
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USA) following the manufacturer’s instructions. Only for experiments in 293T cells, pLTR luciferase plasmids 
(pGL4.10-LTRwt or pGL4.10-LTR-M4 + 5) were transfected 24 h later by using Lipofectamine 3000 (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA). Luciferase activity was measured using the britelite plus Reporter 
Gene Assay System (PerkinElmer Inc., Milan, Italy) at a Victor X2 multilabel plate reader (PerkinElmer Inc., 
Milan, Italy), according to the manufacturer’s instructions. Cells were lysed in 1% Triton-X100-PBS and protein 
concentration was determined by BCA assay (Thermo Scientific Pierce, Monza, Italy). Luciferase signals were 
subsequently normalized to total protein content, according to the manufacturer’s protocol (http://ita.promega.
com/~/pdf/resources/pubhub/cellnotes/normalizing-genetic-reporter-assays/). Each assay was performed in 
duplicate and each set of experiments was repeated at least three times.
Cell Viability Assay. The MTT (3-(4,5-dimethylthiazol 2-yl)-2,5-diphenyltetrazolium bromide, Sigma 
Aldrich, Milan Italy) assay was performed to assess cell viability on silenced cells. 293T cells (6 × 103) were plated 
in 96-well plates and incubated for 24 h. Following siRNA transfection (from 1 nM to 8 nM), cells were incubated 
for an additional 48 h. Control cells (transfected in absence of siRNA) were treated in the exact same conditions. 
Cell survival was evaluated by MTT assay: 10 μ L of freshly dissolved solution of MTT (5 mg/mL in PBS) were 
added to each well, and after 4 h of incubation, MTT crystals were solubilized in solubilization solution (10% 
sodium dodecyl sulphate (SDS) and 0.01 M HCl). After overnight incubation at 37 °C, absorbance was read at 
540 nm. Data were expressed as mean values of at least two individual experiments conducted in triplicate. The 
percentage of cell survival was calculated as follows: cell survival = (Awell − Ablank)/(Acontrol − Ablank) × 100, where 
blank denotes the medium without cells.
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